City of Hope -Duarte Cancer Center

Duarte, California 91010

7 studies enrolling now · 12 studies all time

What they study most

Advanced Metastatic Castration-resistant Prostate Cancer, Advanced Non-small Cell Lung Cancer, Advanced Solid Tumors, Advanced/Metastatic Colorectal Adenocarcinoma, Biochemically Recurrent Prostate Cancer, Breast Cancer, Ductal Carcinoma in Situ, EGFR Mutation, HER2 Mutation, Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), MTAP-deleted Solid Tumors

Studies at this site

• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects — Recruiting now
• DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment — Recruiting now
• A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) — Recruiting now
• A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation — Recruiting now
• First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors — Recruiting now
• A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies — Running, not enrolling
• A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) — Running, not enrolling
• Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors — Completed
• A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors — Completed
• A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers — Completed